March 2021 Volume 7 Issue 4

March 2021

Volume 7, Issue 4

This issue examines the 21st Century Cures Act’s information blocking requirements, blood services around the globe, and more.

Table of Contents

March 2021 Issue

You Make the Call

Reader Responses: How would you treat a patient with aggressive systemic mastocytosis?

Monday, March 1st, 2021
Here’s how readers responded to a You Make the Call question about treatment of bone manifestations and transplantation for systemic mastocytosis. Disclaimer: ASH does not...

Lessons in Legislation

Monday, March 1st, 2021
The American Society of Hematology (ASH) selected Jerome Seid, MD, as its 2020-2021 ASH Congressional Fellow. The Congressional Fellow program aims to connect hematologists...

Guest Commentary: Rise and Rise Again…

Monday, March 1st, 2021
Here, Amrita Krishnan, MD, Nina Shah, MD, and Saad Usmani, MD, reflect on the significance of the swearing in of Kamala Harris, the daughter...

Editor’s Corner: Healing Our Invisible Wounds

Monday, March 1st, 2021
Many patients whose paths cross ours, as hematologists, will inevitably face premature death due to their underlying disease. Yet, we learn from each case,...

March 2021 Issue

Crizotinib Approved for Relapsed/Refractory Systemic ALCL

Monday, March 1st, 2021
Crizotinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children older than one year and young adults...

Daratumumab and Hyaluronidase-fihj Approved for Light Chain Amyloidosis

Monday, March 1st, 2021
The combination of daratumumab and hyaluronidase-fihj and bortezomib, cyclophosphamide, and dexamethasone (D-VCd) was granted accelerated approval for the treatment of adults with newly diagnosed...
The Society Pages

Remembering Art Nienhuis, Thomas Edgington, and more

Monday, March 1st, 2021
Remembering Art Nienhuis (1941 – 2021) Gene therapy pioneer Art Nienhuis, MD, passed away on February 3, 2021, at the age of 79.Dr. Nienhuis was...

Older Age, Pre-Existing Comorbidities Increase Poor Outcomes in Patients With SCD and COVID-19

Monday, March 1st, 2021
Patients with sickle cell disease (SCD) have poor outcomes associated with COVID-19, particularly if they are older or present with end organ damage, acute...
ASH Directions

New Clinical Practice Guidelines for VTE in Cancer, Registration for 2021 Highlights of ASH®...

Monday, March 1st, 2021
Now Published: ASH Clinical Practice Guidelines on VTE in Patients with Cancer ASH’s new clinical practice guideline on the prevention and treatment of venous thromboembolism...

Examining Outcomes Among Hispanic Patients With Multiple Myeloma

Monday, March 1st, 2021
Hispanic and non-Hispanic Black patients with multiple myeloma (MM) more often present with disease at a younger age and with significant renal dysfunction. These...

DDAVP Prevents Post-Intervention Bleeding Complications in Patients With Low von Willebrand Factor Levels

Monday, March 1st, 2021
A recent study suggests 1-desamino-8-D-arginine vasopressin (DDAVP) prevents bleeding in patients with low von Willebrand factor (VWF) levels undergoing major and minor elective procedures....

Can Adding Lenalidomide to Rituximab-MiniCHOP Improve Survival in Older Patients With Diffuse Large B-Cell...

Monday, March 1st, 2021
In a phase III trial of patients age 80 or older with diffuse large B-cell lymphoma (DLBCL), attempts to improve on the standard approach...
WIB_icon

Risk of Subsequent Malignant Neoplasms Is Low in Children With Hodgkin Lymphoma

Monday, March 1st, 2021
A study published in Blood suggests that children and adolescents with intermediate-risk Hodgkin lymphoma have a relatively low cumulative risk of developing subsequent malignant...
WIB_icon

Adults With Hematologic Malignancies and COVID-19 Fare Worse Than Children

Monday, March 1st, 2021
Adults with hematologic malignancies and COVID-19 infection have a substantially higher risk of death compared with children with hematologic malignancies and COVID-19, according to...

Pegcetacoplan Improves Hematologic Response in PNH Treated With Eculizumab

Monday, March 1st, 2021
For patients with paroxysmal nocturnal hemoglobinuria (PNH) who are receiving eculizumab yet have residual anemia, treatment with pegcetacoplan led to broad hemolysis control and...

FDA Accepts IND Application for PBCAR19B

Monday, March 1st, 2021
The FDA cleared Precision BioSciences’ Investigational New Drug (IND) application for its chimeric antigen receptor (CAR) T-cell therapy PBCAR19B. The company will initiate a...

IND Application Cleared for VOR33 in CD33+ Acute Myeloid Leukemia

Monday, March 1st, 2021
The FDA cleared Vor Biopharma’s IND application for its hematopoietic cell therapy VOR33. This decision allows the company to initiate a phase I/IIa clinical...

VLX-1005 Receives Orphan Drug Designation

Monday, March 1st, 2021
The FDA granted orphan drug designation to VLX-1005 as thrombosis prophylaxis in patients with heparin-induced thrombocytopenia (HIT). According to its manufacturer, Veralox Therapeutics, preclinical data...

FDA Issues Guidance for Measuring Viscoelasticity Amid COVID-19 Pandemic

Monday, March 1st, 2021
The FDA has issued immediate guidance for expanding the availability and capability of coagulation systems for measuring whole blood viscoelastic properties to assess hemostasis....

March 2021 Issue

Instant Access: Alarming or Empowering?

Monday, March 1st, 2021
As the 21st Century Cures Act’s information blocking requirements go into effect, clinicians face the realities of increased patient access. Years ago, to share medical...

Pulling Back the Curtain: Bill Blum, MD, and Kristie Blum, MD

Monday, March 1st, 2021
In this edition, Bill Blum, MD, and Kristie Blum, MD, talk about working closely as academic hematologists. Did you both always know you wanted to...

Blood Services Around the Globe

Monday, March 1st, 2021
The COVID-19 pandemic put a spotlight on the patchwork system of blood collection that has developed around the world – and how to improve...

March 2021 Issue

You Make the Call

You Make the Call: How would you treat a patient with aggressive systemic mastocytosis?

Monday, March 1st, 2021
This month, William Shomali, MD, discusses treatment of bone manifestations and transplantation for systemic mastocytosis. And don't forget to check out next month's clinical dilemma...

March 2021 Issue

On location

Researchers Recommend New Processes for Bone Marrow Screening for HLH

Monday, March 1st, 2021
For patients suspected of having hemophagocytic lymphohistiocytosis (HLH), bone marrow biopsy is often used to identify the presence of hemophagocytosis and assess for underlying...
On location

e-IRON: Iron-Deficiency Anemia Management at Warp Speed

Monday, March 1st, 2021
A telemedicine pilot program to triage and expedite the management of patients with iron-deficiency anemia (IDA) who require intravenous (IV) iron allowed clinicians to...
On location

TPO-RAs and ITP: Eltrombopag Induces High Efficacy, But Avatrombopag Offers Advantages

Monday, March 1st, 2021
A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed the thrombopoietin receptor agonist (TPO-RA) eltrombopag in two settings:...
On location

No Difference in CNS Relapse Rate According to Prophylaxis Route

Monday, March 1st, 2021
According to results from a retrospective analysis of central nervous system (CNS) prophylaxis in patients with aggressive non-Hodgkin lymphomas (NHLs), rates of CNS relapse...
On location

Roxadustat Superior to Epoetin Alfa in Patients With Anemia and Dialysis-Dependent Chronic Kidney Disease

Monday, March 1st, 2021
In patients with anemia and dialysis-dependent chronic kidney disease (CKD), treatment with roxadustat led to higher hemoglobin (Hb) levels and a reduced need for...